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Latent effects of fibronectin, a5b1 integrin, aVb5 integrin and the
cytoskeleton regulate pancreatic carcinoma cell IL-8 secretion
AG Lowrie1, DM Salter2 and JA Ross*,1
1Tissue Injury and Repair Group, 6th Floor, Centre for Inflammation Research, University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG,
UK; 2Department of Pathology, University of Edinburgh, Royal Inf irmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK
Interactions between tumour cells and the microenvironment are increasingly recognised to have an influence on cancer progression.
In pancreatic carcinoma, a highly desmoplastic stroma with abnormal extracellular matrix (ECM) protein and interleukin-8 (IL-8)
expression is seen. To investigate whether the ECM may further contribute to abnormalities in the microenvironment by influencing
IL-8 secretion, we cultured the Mia PaCa2 pancreatic carcinoma cell line on fibronectin. This resulted in a dose-dependent increase in
IL-8 secretion, which was RGD dependent and accompanied by cell spreading and proliferation. The role of spreading was assessed
by disruption of the cytoskeleton with cytochalasin D, resulting in a large increase in IL-8 secretion, which was reduced from 31- to
24-fold by fibronectin. This remarkable response was associated with inhibition of spreading and proliferation and represents a novel
cytoskeletal function. To investigate whether it could be accounted for by the loss of integrin-mediated signalling, the expressed a5b1,
aVb5 and a3b1 integrins were inhibited. a5b1 inhibition prevented spreading and proliferation but produced a much smaller rise in
IL-8 secretion than cytochalasin D. aVb5 inhibition alone had only minor effects but when inhibited in combination with a5b1
completely abolished the response to fibronectin. These results reveal latent stimulatory effects of the aVb5 integrin on IL-8 secretion
and suggest that integrin crosstalk may limit the induction of IL-8 secretion by fibronectin. However, the magnitude of IL-8 secretion
induced by cytochalasin cannot be accounted for by integrin signalling and may reflect the influence of another signalling pathway or a
novel, intrinsic cytoskeletal function.
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A view of the tumour as a functional tissue interconnected with the
microenvironment has recently emerged in which the host stroma
participates in the induction, selection and expansion of neoplastic
cells (Liotta and Kohn, 2001; Radisky et al, 2001; Pupa et al, 2002).
The extracellular matrix (ECM) and cytokines are important
mediators of this process whose net effects are determined by a
complex series of interactions. Many cytokines bind to compo-
nents of the normal ECM in an inactive form and are activated
only on degradation of the ECM by a matrix protease (Streuli,
1999). These proteases are secreted mainly by stromal cells
(Crawford and Matrisian, 1996) and may be induced by cytokines
(Saren et al, 1996). Extracellular signals can also alter the
expression of ECM proteins and cytokines, creating feedback
loops that may contribute to tumour development. For example,
the induction of tumour cell matrix protein production by
cytokines has been demonstrated (Rettig et al, 1994). However,
despite evidence in nonmalignant cells (Eierman et al, 1989), the
induction of cytokine secretion in malignant cells by ECM
components is yet to be investigated.
The ECM has been shown to influence multiple cellular
functions including proliferation, apoptosis, adhesion, motility,
gene expression and differentiation (Lupetti et al, 1996; Danen and
Yamada, 2001; Brakebusch et al, 2002; Stupack and Cheresh, 2002).
These responses are mediated by cellular receptors, of which the
integrin family of heterodimeric glycoproteins is the largest and
most ubiquitous. The ligand specificity of an integrin is influenced
by both its a and b subunits, which contribute jointly to the ligand
binding domain. This domain recognises ECM molecules via short
peptide sequences, for example, the RGD sequence of fibronectin
(Pytela et al, 1985). Upon ligation conformational changes and
clustering occur, leading to the accumulation of cytoskeletal and
signalling molecules at areas of plasma membrane termed focal
contacts (Yamada and Miyamoto, 1995; Hynes, 2002). The
integration of signals from multiple ECM molecules and cytokines
is facilitated by the subsequent activation of signalling pathways
and changes in cell shape (Horwitz et al, 1986; Otey et al, 1990;
Maheshwari et al, 1999). Such signalling pathways function
cooperatively in that they can often be activated by either integrins
or soluble factors. For example, the focal adhesion kinase can be
activated by growth factors or integrin clustering (Zachary and
Rozengurt, 1992). MAPK signalling is also known to be induced by
both integrins and soluble mitogens, overexpression of which leads
to anchorage independence (Mansour et al, 1994; Schlaepfer et al,
1994). In contrast, integrin induced changes in cell shape often
function to facilitate the effects of cytokines. In particular,
signalling via the a5b1 integrin has been found to be required
for soluble mitogens to induce proliferation (Miyamoto et al, 1995,
1996; Boudreau and Jones, 1999).
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Pancreatic carcinoma is a highly malignant tumour in which an
intense desmoplastic reaction and an abnormal stroma are
commonly observed. In common with other tumours, alterations
in the expression of cytokines and ECM proteins have been
demonstrated (Riedl et al, 1992; Juliano and Varner, 1993; Danen
et al, 1994; Mizejewski, 1999). In particular, marked increases in
fibronectin, type I collagen and type III collagen levels are seen
(Gress et al, 1995). Cytokine expression is also altered and, in
particular, interleukin-8 (IL-8), which is not found in the normal
pancreas, is produced (Di Sebastiano et al, 2000). A member of the
CXC chemokine family, IL-8 has functions important to the
progression of pancreatic carcinoma including stimulation of
autocrine growth and angiogenesis (Shi et al, 1999; Le et al, 2000).
Its production has been correlated with the metastatic potential of
pancreatic carcinoma cells in nude mice (Bruns et al, 1999; Shi
et al, 1999) and is regulated by factors altered in tumour
microenvironments including nitric oxide, hypoxia, cytokines
and acidosis (Shi et al, 2001; Xie, 2001). However, it is not yet
known whether IL-8 production may be regulated by signals from
the ECM. We previously screened a range of pancreatic carcinoma
cell lines and found that Mia PaCa2 cells produce significant levels
of IL-8 (Wigmore et al, 2002). Here, we describe the influence of
fibronectin on IL-8 secretion and the secretion-associated
phenotypic changes of cell spreading and proliferation. The
relationship between cytoskeletal organisation and IL-8 secretion
and the contribution of integrins to this relationship is further
assessed.
MATERIALS AND METHODS
ECM and antibodies
The ECM molecules and control molecules employed were: type I
collagen (Southern Biotech, UK), fibronectin (Sigma, UK), BSA
(Sigma, UK), GRGDSP peptides and GRADSP peptides (Calbio-
chem-Novabiochem, Nottingham, UK). Antibodies and specifi-
cities were P1B5 (a3 integrin, Gibco-BRL, UK), CLB-705 (a5
integrin, Chemicon, UK), AMF-7 (aV integrin, Immunotech, UK),
P1F6 (aVb5 integrin, Gibco-BRL, UK) and P4C10 (b1 integrin,
R&D systems, UK). Additional antibodies used in flow cytometry
were TS2/7 (a1 integrin, T Cell Sciences), AK7 (a2 integrin,
Serotec), GoH3 (a6 integrin, Serotec), 23C6 (aVb3 integrin, kind
gift from M Horton, cf. Horton et al, 1985), TS2/16 (b1 integrin,
kind gift from J Sanchez-Madrid, cf. Arroyo et al, 1992), CD61 (b3
integrin, Dako), 3E1 (b4 integrin, Chemicon) and mouse Ig isotype
controls (Sigma, UK). Cytochalasin D was obtained from Sigma,
UK.
Cell culture
The Mia PaCa2 human pancreatic carcinoma cell line was obtained
from the European Tissue Culture Collection (ECACC, Porton
Down, UK). Cells were maintained in 250 cm2 flasks (Costar, UK)
with Dulbecco’s modified Eagle’s medium (Gibco-BRL, UK)
plus 5% FCS. Culture media were supplemented with 50 IU ml1
penicillin, 50 mg ml1 streptomycin and 2 mM L-glutamine
(Gibco-BRL, UK). Cell culture flasks were incubated at 371C
in a 5% CO2 in air atmosphere and the medium changed every
3–4 days.
Before use in experiments, cell viability and concentration was
assessed by trypan blue exclusion. Cells were diluted to a
concentration of 1 105 cells ml1 in serum-free medium contain-
ing soluble molecules where appropriate. A total of 1.2 105 cells
were then added to each experimental well in a 24-well plate
(Costar, UK). Viability was greater than 98% in all experiments.
Cells were incubated for 72 h. Multiwell plates were then
centrifuged at 300 g for 5 min. The resulting supernatants were
removed and centrifuged at 13 000 r.p.m. for 1 min in preparation
for ELISAs.
For experiments with coated plates, flat-bottomed 24-well plates
(Nunclon) were coated with 250 ml well1 of a range of concentra-
tions of the above ECM proteins diluted in PBS. Plates were then
dried overnight at room temperature in a laminar flow air cabinet.
Nonspecific binding sites on well surfaces were blocked by the
application of 10% BSA. Wells coated with BSA alone served as
negative controls. Following incubation for 1 h at 371C, BSA was
discarded and wells washed twice with PBS prior to use. Cell shape
was examined at 0, 24, 48 and 72 h of culture using an inverted
light microscope.
IL-8 ELISAs
Interleukin-8 ELISAs were performed as described previously
(Wigmore et al, 1997). Plates were read at a wavelength of 450 nm
using the Dynatech MR5000 plate reader and Assayzap interpreta-
tion program. Samples and standards were tested in triplicate and
the values given represent the mean values for each sample as
calculated from the standard curve.
Cell counts
Cell counts were carried out by a direct count of cells within
marked fields in the inverted light microscope. Plates were
examined for comparable fields, which were then marked with a
fine-tipped laboratory marker and the magnification was increased
to  20. A graticule was attached to the microscope and lined up
with an identifiable feature of the dot and cells within the grid of
the graticule counted. Cells were initially counted 4 h after seeding
to allow for settling to the bottom of the well, and again after 72 h
under experimental conditions. To allow for intrawell variation,
four fields per well with 80 –120 cells per field were counted. On
replacing the field and recounting errors were less than 5%.
Flow cytometry
Following removal from culture flasks cells were resuspended in
PBSþ 1% BSAþ azide and counted before being processed for
flow cytometry using a panel of antibodies. The secondary
antibody used was sheep anti-mouse fluoroisothiocyanate con-
jugate (FITC, Sigma, UK). Samples were analysed using a Coulter
Epics XL-MCL flow cytometer.
Statistical analysis
Results were analysed with a two-tailed Mann–Whitney test. P-
values of o0.05 were taken to indicate statistical significance.
RESULTS
Effects of fibronectin
The effect of fibronectin on IL-8 secretion by Mia cells was
determined by culture in matrix-coated wells. Culture on
fibronectin for 72 h resulted in a dose-dependent increase in IL-8
secretion, which was statistically significant (Po0.05) for coating
concentrations of 0.1 mg ml1 and higher and plateaued at a
concentration of 10 mg ml1 (Figure 1A and B).
Simultaneous assay of cell numbers revealed a dose-dependent
increase in numbers (Figure 1A). This was significant for coating
concentrations of 0.1mg ml1 and above (Po0.05). When IL-8
secretion was expressed as a function of cell number, fibronectin
had no significant effect (Figure 1B).
When grown on fibronectin, Mia PaCa2 cells grew as single,
spread cells, which were fusiform in shape (Figure 1C). In 10%
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BSA-coated wells, no cell spreading was observed and cells
maintained a rounded morphology (Figure 1D and E)
Culture of Mia PaCa2 cells for 72 h in the presence of soluble
GRGDSP peptides abolished the effects of fibronectin on IL-8
secretion, proliferation and spreading (Figure 2A–C). Control
GRADSP peptides did not affect the response, demonstrating that
the influence of fibronectin was RGD dependent.
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Figure 1 Effect of fibronectin and type I collagen on Mia PaCa2 cell IL-8
secretion, number and spreading. Culture of Mia PaCa2 cells on fibronectin
for 72 h produced a dose-dependent increase in IL-8 and cell number (A).
However, when expressed as IL-8 per cell, this was not significant (B).
Values are expressed as a percentage of those obtained for culture on BSA.
When cultured on fibronectin cells took on a fusiform, spread appearance
(C) in comparison with the rounded appearance seen when cultured on
BSA (D). *Po0.05 vs untreated control.
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Figure 2 GRGDSP inhibition experiments. Following 72 h of culture
GRGDSP peptides inhibited fibronectin-induced IL-8 secretion (A) and
proliferation (B). No significant effect was seen with control GRADSP
peptides. When IL-8 was expressed per percentage change in cell numbers,
fibronectin resulted in a small drop in secretion in these experiments. This
was abolished by GRGDSP peptides but not by GRADSP, suggesting that
the fibronectin RGD motif is critical to its effects. *Po0.05 vs untreated
control.
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To further investigate the relationship between cell numbers and
IL-8 secretion in fibronectin-coated wells, time-course experiments
were performed. From 0 to 48 h of culture, the levels of IL-8 per
well increased at a constant rate and were approximately equal in
fibronectin- and BSA-coated wells (Figure 3A). From 48 to 72 h, the
rate of IL-8 secretion was greater in fibronectin-coated wells.
Subsequently, the rate of secretion was similar in both fibronectin-
and BSA-coated wells. Cell numbers rose only in fibronectin-
coated wells, with a 235% increase over 120 h (Figure 2B). When
IL-8 per cell was assessed, the overall effect of fibronectin was to
decrease secretion (Figure 3C). Cell spreading on fibronectin was
apparent from 4 h onwards, and did not change over the course of
the experiments.
These findings suggested firstly that cell proliferation was not
dependent on IL-8 secretion, as cell numbers in fibronectin-coated
wells rose before IL-8 levels differed from those in BSA-coated
wells, and secondly that IL-8 secretion was not dependent on cell
numbers, as rates of secretion per cell differed in fibronectin- and
BSA-coated wells. However, it remained possible that both IL-8
levels and proliferation might be separately influenced by
spreading. Actin polymerisation and cytoskeletal organisation
were therefore inhibited with cytochalasin D.
Inhibition of the cytoskeleton
Cells were cultured for 72 h on fibronectin- or BSA-coated wells in
the presence of 1 mg ml1 of cytochalasin D. This resulted in an
increase in IL-8 secretion by a factor of 24-fold in fibronectin-
coated wells and by a factor of 31-fold in BSA-coated wells
(Figure 4A). In wells treated with the cytochalasin D carrier vehicle
DMSO, only a small increase in IL-8 secretion was observed. In
contrast, addition of cytochalasin D to wells coated with
fibronectin prevented rather than increased fibronectin-induced
cell proliferation (Figure 4B). In BSA-coated control wells,
cytochalasin D had no significant effect on cell numbers. When
IL-8 was expressed as pg per percentage change in cell number,
increases in IL-8 secretion of similar ratios were seen and
fibronectin retained its inhibitory effect (Figure 4C). Cytochalasin
did not induce loss of adherence or obvious apoptosis over the
time period examined. DMSO slightly inhibited fibronectin-
induced cell proliferation but had no effect in BSA-coated control
wells.
Cytochalasin D prevented fibronectin-induced cell spreading
(Figure 4D). On fibronectin-coated wells, the cells firmly adhered
to the substratum. DMSO did not affect cell shape.
Expression of adhesion molecules by Mia PaCa2 cells
Flow cytometry was performed to identify integrins, which might
be responsible for the cytoskeleton- and fibronectin-induced
effects. The a3 integrin was expressed by 79.2% of Mia PaCa2
cells, b1 integrin by 55.5%, aVb5 integrin by 27.8%, aV integrin by
25.6% and the a5 integrin by 19.7%. All other integrins were
expressed by less than 5% of cells.
To further investigate the relationship between IL-8 secretion,
cell proliferation and spreading, inhibition experiments were
performed.
Integrin inhibition experiments
b Integrins Addition of either anti-aVb5 (P1F6) or anti-b1
(P4C10) integrin antibodies to fibronectin-coated wells resulted
in an increase in IL-8 levels in comparison to untreated or IgG-
treated control wells following 72 h of culture (Figure 5A). Anti-b1
integrin antibodies also increased IL-8 levels in BSA-coated control
wells. Nonspecific IgG antibodies did not significantly affect IL-8
secretion in either fibronectin- or BSA-coated wells.
Cell proliferation was significantly inhibited (Po0.05) only by
anti-b1 integrin antibodies, despite a slight decrease seen in IgG-
treated control wells (Figure 5B). In contrast with its effects on IL-8
secretion, the anti-aVb5 antibody P1F6 did not inhibit prolifera-
tion. Neither anti-b1 nor anti-aVb5 integrin antibodies had any
effect on cell numbers in BSA-coated control wells. When results
were interpreted as IL-8 per cell, fibronectin was observed to
decrease IL-8 secretion. The addition of anti-b1 integrin antibodies
reversed this effect, increasing IL-8 levels to 168% of control, while
increasing levels of IL-8 produced by cells cultured on BSA to only
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Figure 3 Fibronectin time course. An increase in the rate of IL-8
secretion was observed in wells coated with 1mg ml1 fibronectin before
any rise in secretion in BSA-coated wells (A). Interleukin-8 levels continued
to rise at the same rate after 72 h in fibronectin- and BSA-coated wells. Cell
numbers rose only in fibronectin-coated wells and slowed after 72 h (B).
However, when results were expressed as IL-8 per cell (C), it was apparent
that at 96 and 120 h secretion was decreased in fibronectin-coated wells.
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128% of control (Figure 5C). Anti-aVb5 integrin antibodies did not
significantly affect IL-8 per cell.
Cell morphology was unaffected by aVb5 inhibition with cells
remaining fully spread on fibronectin. Culture in the presence of
anti-b1 integrin antibodies resulted in a round, unspread
morphology. Neither anti-aVb5 integrin nor anti-b1 integrin
antibodies affected cell morphology in BSA-coated wells. In
summary, blockade of the b1 integrin resulted in an increase in
IL-8 secretion on fibronectin and interaction with the b1 integrin
was required for fibronectin-induced cell proliferation and
spreading, whereas inhibition of aVb5 had little effect.
a Integrins At 72 h, IL-8 levels in wells coated with fibronectin
were increased by both anti-a5 (CLB-705) and anti-aV (AMF-7)
antibodies (Figure 5A). Anti-a5 antibodies also increased the
amount of IL-8 per well in wells coated with BSA. Anti-a5 and anti-
aV antibodies in combination produced a significant inhibition of
the effect of fibronectin on IL-8 secretion but did not influence IL-
8 secretion in BSA-coated wells. Anti-a3 integrin (P1B5) and
nonspecific IgG antibodies did not affect IL-8 secretion.
Cell proliferation was inhibited in wells treated with anti-a5
integrin antibodies alone and in combination with anti-aV
antibodies (Figure 5B). Anti-aV integrin antibodies alone, anti-
a3 and nonspecific IgG antibodies did not affect cell numbers in
fibronectin-coated wells. None of the antibodies used affected cell
numbers in BSA-coated wells. When IL-8 was expressed per
percentage change in cell number, anti-a5 integrin antibodies were
observed to have a similar effect to anti-b1 antibodies, increasing
IL-8 secretion in fibronectin-coated wells more than in BSA-coated
wells (Figure 5C). Anti-aV integrin antibodies both alone and in
combination with anti-a5 antibodies did not affect IL-8 per cell.
However, it should be noted that alone, this was due to a lack of
effect on the response to fibronectin and in combination with anti-
a5 antibodies due to a complete inhibition of the responses to both
fibronectin and anti-a5 antibodies.
Fibronectin-induced cell spreading was inhibited by the
addition of anti-a5 integrin antibodies but not by anti-a3 integrin,
anti-aV or nonspecific IgG antibodies at either 1 or 2 mg ml1
concentrations.
In summary, the aV integrin appears to stimulate IL-8 secretion
when the a5 integrin is inhibited and, consequently, cell spreading
and proliferation are prevented. This effect is apparent on both
BSA and fibronectin but greater on the latter, in contrast with the
effect observed on treatment with cytochalasin, when fibronectin
decreased IL-8 production.
DISCUSSION
When Mia PaCa2 cells were cultured on fibronectin, a response
that involved IL-8 production, proliferation and spreading was
observed. All of these effects were RGD dependent, consistent with
the known importance of the RGD motif to fibronectin-induced
proliferation and spreading and its requirement for cytokine
induction in certain cell types (Takizawa et al, 1995). Taken with
the close relationship between increases in IL-8 production and
cell numbers, which suggested that IL-8 secretion may directly
reflect of cell number, this raised the possibility that a single, RGD-
dependent mechanism might mediate the entire cellular response.
However, time-course experiments revealed that the overall effect
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Figure 4 Treatment of Mia PaCa2 cells with 1 mg ml1 cytochalasin D.
Culture of Mia PaCa2 cells for 72 h in the presence of cytochalasin D
resulted in a 24-fold increase in IL-8 secretion on fibronectin-coated wells
and a 31-fold increase in IL-8 secretion on BSA-coated control wells (A).
Cytochalasin treatment also inhibited proliferation in fibronectin-coated
wells in comparison with no treatment or treatment with the cytochalasin
carrier vehicle DMSO (B). When IL-8 levels were expressed as a fraction
of the percentage change in cell numbers, a large increase in secretion was
still apparent and remained lower on fibronectin than on BSA. Fibronectin-
induced cell spreading was prevented by cytochalasin (D). *Po0.05 vs
untreated control.
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of fibronectin was to decrease IL-8 secretion per cell, as after 72 h
IL-8 levels in fibronectin-coated wells did not continue to diverge
from levels in BSA-coated wells despite the presence of more cells.
This implies that secretion is influenced by another factor, as was
the relationship purely direct IL-8 production per cell would
remain constant regardless of cell number. Crosslinking of the
a3b1 integrin has been demonstrated to limit IL-8 secretion in
epithelial cells, and integrin ligation might therefore directly
inhibit cytokine production. However, increased cell density has
also been reported to limit IL-8 secretion in human polymorpho-
nuclear leucocytes (Hattar et al, 2001) and could also play a role,
although in pancreatic tumours a high cell density is associated
with increased IL-8 secretion (Shi et al, 2001). It is therefore more
likely that increasing cell density would stimulate Mia PaCa2 cell
secretion between 48 and 72 h, shortly after the period of
maximum proliferation on fibronectin. Cell cycling may also
influence IL-8 production, and has been reported to inhibit IL-8
secretion in keratinocytes (Wilmer and Luster, 1995). This
regulation of IL-8 production clearly differs from the normal
pancreas, which does not secrete IL-8 (Di Sebastiano et al, 2000),
potentially due to microenvironmental influence or a regulatory
pathway lost in tumour cells.
The spreading observed in cells cultured on fibronectin
suggested that cytoskeletal signalling might play a role in Mia
PaCa2 cell IL-8 regulation. Previous studies have suggested that in
functional terms, cytoskeletal signalling is mainly facilitative to
other pathways (Miyamoto et al, 1995, 1996). We were therefore
surprised to find that inhibition of the cytoskeleton with
cytochalasin D resulted in such a large increase in IL-8 secretion
and yet did not abolish the inhibitory effect of fibronectin. Of
studies that have examined the effect of cytochalasin on cytokine
production, only one has documented a similar effect, in which it
was found that T-lymphocyte activation and IL-2 production were
stimulated by binding of cytochalasin to high-affinity sites in actin
(Geppert and Lipsky, 1990). This suggests that IL-8 induction by
cytochalasin could be due to the loss of an intrinsic inhibitory
effect of the cytoskeleton, rather than loss of facilitation of another
inhibitory stimulus. However, in contrast to Mia PaCa2 cells, T-cell
proliferation was not inhibited by cytochalasin, which may reflect
the fact that proliferation in our system differs by being
fibronectin, and therefore cell shape, dependent. Whatever the
mechanism, it is clear that there is significant latent potential for
cytoskeletal dysregulation to induce IL-8 production. That
fibronectin limited this in our experiments is consistent with its
proposed antitumorigenic role and suggests that it may be capable
of influencing IL-8 production via a noncytoskeletal mechanism,
possibly mediated via the a5b1 or aVb5 integrins (Taverna et al,
1998; Armstrong and Armstrong, 2000).
When either subunit of a5b1 was inhibited on either fibronectin
or BSA, a similar qualitative effect to that of cytochalasin was
observed, with increased secretion of IL-8 per cell. On fibronectin,
spreading and proliferation were also inhibited and these
similarities suggest that loss of a5b1 function could partially
account for the effect of cytoskeletal inhibition. However, although
the magnitude of the rise in IL-8 was significant, with secretion per
cell increasing to 168% of BSA controls, it was far less than that
induced by cytochalasin. This suggests that although a5b1 can
stimulate cytoskeletal organisation and thereby limit IL-8 secre-
tion, the cytoskeleton must influence secretion by at least one
additional mechanism, consistent with the finding that fibronectin
maintains an inhibitory effect despite cytochalasin treatment. A
range of growth factors and cytokines are known to signal via the
cytoskeleton and some, for example, IL-10 and TGFb, are known to
inhibit IL-8 secretion (de Waal Malefyt et al, 1991; Mendez-
Samperio et al, 2002). These cytokines have also been implicated in
pancreatic carcinogenesis (Bellone et al, 1999; Nicolas and Hill,
2003). Interleukin-8 production secondary to the loss of their
effects may therefore be an alternative explanation to the loss of
intrinsic cytoskeletal function, which might account for the effect
of cytochalasin. In either case, the evidence suggests that the
cytoskeleton integrates several inputs in the regulation of IL-8
production.
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Figure 5 Effect of soluble anti-integrin antibodies on fibronectin-induced
IL-8 secretion. Cells were cultured on either fibronectin or BSA
substratums for 72 h prior to assays. The effects of fibronectin on both
IL-8 secretion (A) and cell numbers (B) were abolished by both lone anti-
b1 integrin antibodies and by anti-a5 and -aV antibodies used in
combination. Use of the anti-a5 antibody alone did not affect IL-8 levels
but abolished fibronectin-induced cell proliferation. Single use of the anti-
aV antibody resulted in increased IL-8 levels but did not affect proliferation.
When IL-8 levels were expressed as a fraction of the percentage change in
cell numbers, secretion was decreased by fibronectin in these experiments
(C). This decrease was not affected by control IgG or anti-a3 or -aVb5
antibodies. Anti-b1 and a5 antibodies resulted in an increase in IL-8
secreted per cell, which was greater on fibronectin than on BSA. Anti-aV
antibodies both alone and in combination with anti-a5 abolished the
difference between fibronectin and BSA, although in the case of anti-aV
alone this was due to an identical increase in cell proliferation and IL-8
secretion, whereas anti-aV and -a5 in combination abolished both.
*Po0.05 vs untreated control.
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As the only other fibronectin receptor expressed by Mia PaCa2
cells, the aVb5 integrin is highly likely to be responsible for the
effects seen on a5b1 inhibition. This is supported by the abolition
of all cellular responses to fibronectin by dual inhibition of a5b1
and aVb5. Therefore, aVb5 appears to have a stimulatory effect on
IL-8 secretion, which is normally inhibited or masked by a5b1
function. This is a novel role for the aVb5 integrin and also for
interintegrin crosstalk, which has previously been shown to
influence cell adhesion and spreading, but never cytokine secretion
(Marshall et al, 1995; Bax et al, 2003). In turn, it suggests that a5b1
normally functions to limit IL-8 secretion per cell, while at the
same time increasing proliferation and therefore the number of
secreting cells. Such a role is also unreported in other systems,
where a5b1 mediates the induction of cytokines. However, a model
for inhibition does exist in the a3b1 integrin, which has been
shown to limit IL-8 induction by cytokines in epithelial cells
(Lubin et al, 2003). Whether the effect of a5b1 is cytoskeleton
dependent or independent is unclear. In favour of the former, it is
clear that inhibition of either a5b1 or the cytoskeleton results in a
large increase in IL-8 secretion and a5b1 induces cytoskeletal
organisation through induction of spreading. However, even when
the cytoskeleton was disrupted, fibronectin maintained an ability
to limit IL-8 secretion, in contrast to the effect seen on a5b1
inhibition, when IL-8 levels in fibronectin-coated wells rose to
above those in BSA-coated wells. Similarly, the crosstalk between
a5b1 and aVb5 may be mediated by any of the several
mechanisms. At the most basic level, inhibition of a5b1 may
result in an increase in the number of available RGD sites to
which aVb5 can bind. Alternatively, the integrins could interact
via shared signalling pathways, alterations in ligand affinities
or by altering fibronectin assembly, and thereby extracellular
feedback (Tomatis et al, 1999; Danen et al, 2002; Perruzzi et al,
2003).
The latent functions of the cytoskeleton and integrins we have
described may have significant implications, as it is increasingly
recognised that the activation of latent pathways can cause failure
of otherwise promising anticancer agents. The targeting of
nonredundant signalling ‘nodes’ has subsequently been suggested
and integrins have been proposed as one of these (Cui and Lee,
2004). However, our results suggest they are perhaps not as
functionally exclusive as previously thought and that major signal
integration may occur at the level of the cytoskeleton. Despite this,
combination therapies aimed at integrins and other mediators of
cell–microenvironment interactions have shown promising results
in other conditions (Anaya-Prado et al, 1998). The identification of
the combinations of extracellular and intracellular effects of the
microenvironment that are critical to tumour progression should
facilitate such approaches in cancer.
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